Jump to content

Genedata Profiler Receives Bio-IT World 2022 Innovative Practices Award in Precision Medicine

Innovative solution digitalizes translational research by democratizing data, harmonizing data analytics, and leveraging AI to streamline the development of novel biotherapeutics.

May 3, 2022

Basel, Switzerland—May 5, 2022 — Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced that its innovative digital solution, Genedata Profiler®, a data integration and analytics system for translational and clinical research, has won the Bio-IT World 2022 Innovative Practices Award in the category of Personalized & Translational Medicine. Genedata Profiler, a major component of the Genedata Biopharma Platform, enables biopharmaceutical companies to significantly accelerate the development process of precision medicines and increase clinical trial success. This is achieved by facilitating the use of big data, democratizing data access within large organizations, and automating highly complex R&D workflows at the intersection of pre-clinical and clinical research.  

The combination of multi-omics, imaging, and biomarker data, with phenotype and clinical data, has been recognized as an important asset in research and development. Yet the complexity, diversity, and vast amount of data generated across the R&D life cycle, accompanied by the biopharma industry’s historically siloed data management approach, impede the effective use of big data and its translation into actionable insights. Genedata Profiler has been developed in close collaboration with industry leaders to address these challenges, and this award further validates the value that this solution can bring to the biopharma industry.

Genedata customers successfully leverage the software to integrate pre-clinical, clinical, and RWE multimodal data to develop novel biomarker-driven biotherapeutics and design smarter clinical trials. As a GxP validated platform, Genedata Profiler operates at all stages of biopharmaceutical R&D from exploratory preclinical data analysis to meta-analysis across late-stage clinical studies. By supporting the whole innovation cycle from data harmonization across technologies and projects, results interpretation based on intuitive visualizations, and hypothesis generation, the platform substantially reduces operational costs and significantly increases productivity. Scientists using the platform also highlight how the data-driven culture, supported by the technical solution, breaks the company’s data silos enabling more effective day-to-day work, as well as seamless real-time inter-and intra-organizational collaboration.

Based on a workflow concept, Genedata Profiler allows users to unlock the full potential of big data and is critical for advancing precision medicine. Genedata continuously develops the software platform to stay at the forefront of science & technology and provides the foundation for innovative artificial intelligence-based approaches by supporting AI-based model development. Thanks to flexible interfaces to a broad range of data analytics and visualization methods, Genedata Profiler enables the generation of novel scientific insights, which users emphasize as one of the main benefits of adopting the platform.

“We are honored to win our third Bio-IT Innovative Practices Award,” said Othmar Pfannes, Ph.D., CEO of Genedata. “This award validates our collaborative approach, which focuses on partnering with industry innovators to digitalize complex biopharma R&D processes. We remain committed to supporting our partners to efficiently discover and deliver important precision medicines as quickly as possible.” 

About Genedata

Genedata transforms data into intelligence with innovative software solutions that incorporate extensive biopharma R&D domain knowledge. Multinational biopharmaceutical organizations and cutting-edge biotechs around the globe rely on Genedata to digitalize and automate data-rich and complex R&D processes. From early discovery all the way to the clinic, Genedata solutions help maximize the ROI in R&D expenditure. Founded in 1997, Genedata is headquartered in Basel, Switzerland with additional offices in Boston, London, Munich, San Francisco, Singapore, and Tokyo.
www.genedata.com
LinkedIn | Twitter | YouTube

Contact

Allison Kurz
Genedata
Public Relations
pr@genedata.com

Disclaimer

The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.

About Genedata

Genedata transforms data into intelligence with innovative software solutions that incorporate extensive biopharma R&D domain knowledge. Multinational biopharmaceutical organizations and cutting-edge biotechs around the globe rely on Genedata to digitalize and automate data-rich and complex R&D processes. From early discovery all the way to the clinic, Genedata solutions help maximize the ROI in R&D expenditure. Founded in 1997, Genedata is headquartered in Basel, Switzerland with additional offices in Boston, London, Munich, San Francisco, Singapore, and Tokyo.
www.genedata.com
LinkedIn | Twitter | YouTube

Contact

Allison Kurz
Genedata
Public Relations
pr@genedata.com

Disclaimer

The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.